Financial Report: Abbott 4Q

Abbott 4Q

4Q Revenues: $8.8 billion (+11%)

4Q Earnings: $1.5 million (flat)

FY Revenues: $30.7 billion (+4%)

FY Revenues: 5.7 billion (+18%)

Comments: Worldwide pharmaceutical sales were up 5% to $4.8 billion in the quarter. International Pharmaceutical sales accounted for $2.5 billion and U.S. sales, $2.3 billion. Humira sales were $1.7 billion (+23%) and Niaspan sales were up 15% to $254 million. TriCor/Trilipix sales were $419 million (-8%). Kaletra sales were flat at $378 million. Depakote sales dropped 62% to $102 million due to generic competition. Exchange rates favorably impacted sales in the quarter by 2.5%. Nutritional sales were $1.4 billion, diagnostic sales were $975 million and vascular sales were $723 million, all up 9%. For the year, Worldwide pharmaceutical sales were $16.5 billion (-1%). International sales accounted for $8.7 billion and U.S. sales, $7.8 billion. Humira sales for the year reached $5.5 billion (+21%).